Header Logo

Connection

KENNETH R HESS to Proportional Hazards Models

Back to Details
This is a "connection" page, showing publications KENNETH R HESS has written about Proportional Hazards Models.
KENNETH R HESS
Connection Strength
0.813
Proportional Hazards Models
  1. Getting more out of survival data by using the hazard function. Clin Cancer Res. 2014 Mar 15; 20(6):1404-9.
    View in: PubMed
    Score: 0.257
  2. Hazard function estimators: a simulation study. Stat Med. 1999 Nov 30; 18(22):3075-88.
    View in: PubMed
    Score: 0.096
  3. Graphical methods for assessing violations of the proportional hazards assumption in Cox regression. Stat Med. 1995 Aug 15; 14(15):1707-23.
    View in: PubMed
    Score: 0.072
  4. Assessing time-by-covariate interactions in proportional hazards regression models using cubic spline functions. Stat Med. 1994 May 30; 13(10):1045-62.
    View in: PubMed
    Score: 0.066
  5. Impact of phase II trials with progression-free survival as end-points on survival-based phase III studies in patients with anaplastic gliomas. BMC Cancer. 2007 Jun 22; 7:106.
    View in: PubMed
    Score: 0.041
  6. Multifaceted end points in brain tumor clinical trials: cognitive deterioration precedes MRI progression. Neuro Oncol. 2003 04; 5(2):89-95.
    View in: PubMed
    Score: 0.030
  7. Response and progression in recurrent malignant glioma. Neuro Oncol. 1999 10; 1(4):282-8.
    View in: PubMed
    Score: 0.024
  8. Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab. JAMA Oncol. 2017 Apr 01; 3(4):509-515.
    View in: PubMed
    Score: 0.020
  9. Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials. Oncotarget. 2016 Sep 27; 7(39):64421-64430.
    View in: PubMed
    Score: 0.019
  10. Intratumoral heterogeneity: Role of differentiation in a potentially lethal phenotype of testicular cancer. Cancer. 2016 06 15; 122(12):1836-43.
    View in: PubMed
    Score: 0.019
  11. Development of a model to predict breast cancer survival using data from the National Cancer Data Base. Surgery. 2016 Feb; 159(2):495-502.
    View in: PubMed
    Score: 0.018
  12. Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation. Ann Oncol. 2015 May; 26(5):1012-1018.
    View in: PubMed
    Score: 0.017
  13. Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2-positive metastatic breast cancer. Cancer. 2014 Jul 01; 120(13):1932-8.
    View in: PubMed
    Score: 0.016
  14. The prognostic impact of age in patients with triple-negative breast cancer. Breast Cancer Res Treat. 2013 Apr; 138(2):591-9.
    View in: PubMed
    Score: 0.015
  15. DNA mismatch repair gene polymorphisms affect survival in pancreatic cancer. Oncologist. 2011; 16(1):61-70.
    View in: PubMed
    Score: 0.013
  16. Insulin-like growth factor axis gene polymorphisms and clinical outcomes in pancreatic cancer. Gastroenterology. 2010 Aug; 139(2):464-73, 473.e1-3.
    View in: PubMed
    Score: 0.012
  17. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol. 2009 Nov; 10(11):1037-44.
    View in: PubMed
    Score: 0.012
  18. Effect of timing of metastasis/disease recurrence and histologic differentiation on survival of patients with advanced gastric cancer. Cancer. 2007 Nov 15; 110(10):2186-90.
    View in: PubMed
    Score: 0.010
  19. Survival prediction in patients with glioblastoma multiforme by human telomerase genetic variation. J Clin Oncol. 2006 Apr 01; 24(10):1627-32.
    View in: PubMed
    Score: 0.009
  20. Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. J Clin Oncol. 2005 Nov 20; 23(33):8331-9.
    View in: PubMed
    Score: 0.009
  21. 13-cis-retinoic acid in the treatment of recurrent glioblastoma multiforme. Neuro Oncol. 2004 Jul; 6(3):253-8.
    View in: PubMed
    Score: 0.008
  22. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg. 2004 Jun; 239(6):818-25; discussion 825-7.
    View in: PubMed
    Score: 0.008
  23. The expression of PAX6, PTEN, vascular endothelial growth factor, and epidermal growth factor receptor in gliomas: relationship to tumor grade and survival. Clin Cancer Res. 2003 Aug 15; 9(9):3369-75.
    View in: PubMed
    Score: 0.008
  24. Patterns of expression of Rb and p16 in astrocytic gliomas, and correlation with survival. Int J Oncol. 2000 Nov; 17(5):963-9.
    View in: PubMed
    Score: 0.006
  25. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999 Aug; 17(8):2572-8.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.